Cargando…

Optimizing weight control in diabetes: antidiabetic drug selection

CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, S, Kalra, B, Unnikrishnan, AG, Agrawal, N, Kumar, S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047980/
https://www.ncbi.nlm.nih.gov/pubmed/21437098
http://dx.doi.org/10.2147/DMSOTT.S11941
_version_ 1782199113506357248
author Kalra, S
Kalra, B
Unnikrishnan, AG
Agrawal, N
Kumar, S
author_facet Kalra, S
Kalra, B
Unnikrishnan, AG
Agrawal, N
Kumar, S
author_sort Kalra, S
collection PubMed
description CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1. Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs.
format Text
id pubmed-3047980
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30479802011-03-23 Optimizing weight control in diabetes: antidiabetic drug selection Kalra, S Kalra, B Unnikrishnan, AG Agrawal, N Kumar, S Diabetes Metab Syndr Obes Evidence 2 Practice CLINICAL QUESTION: Which antidiabetic drugs provide optimal weight control in patients with type 2 diabetes? RESULTS: Metformin reduces weight gain, and may cause weight loss, when given alone or in combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin therapy are conflicting. Insulin detemir provides weight control along with glycemic control. IMPLEMENTATION: Weight gain is considered an inevitable part of good glycemic control using conventional modalities of treatment such as sulfonylureas.1. Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, should be encouraged as monotherapy, or in combination with other drugs. Dove Medical Press 2010-08-24 /pmc/articles/PMC3047980/ /pubmed/21437098 http://dx.doi.org/10.2147/DMSOTT.S11941 Text en © 2010 Kalra et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Evidence 2 Practice
Kalra, S
Kalra, B
Unnikrishnan, AG
Agrawal, N
Kumar, S
Optimizing weight control in diabetes: antidiabetic drug selection
title Optimizing weight control in diabetes: antidiabetic drug selection
title_full Optimizing weight control in diabetes: antidiabetic drug selection
title_fullStr Optimizing weight control in diabetes: antidiabetic drug selection
title_full_unstemmed Optimizing weight control in diabetes: antidiabetic drug selection
title_short Optimizing weight control in diabetes: antidiabetic drug selection
title_sort optimizing weight control in diabetes: antidiabetic drug selection
topic Evidence 2 Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047980/
https://www.ncbi.nlm.nih.gov/pubmed/21437098
http://dx.doi.org/10.2147/DMSOTT.S11941
work_keys_str_mv AT kalras optimizingweightcontrolindiabetesantidiabeticdrugselection
AT kalrab optimizingweightcontrolindiabetesantidiabeticdrugselection
AT unnikrishnanag optimizingweightcontrolindiabetesantidiabeticdrugselection
AT agrawaln optimizingweightcontrolindiabetesantidiabeticdrugselection
AT kumars optimizingweightcontrolindiabetesantidiabeticdrugselection